Orally Administered Halofuginone-Loaded TPGS Polymeric Micelles Against Triple-Negative Breast Cancer: Enhanced Absorption and Efficacy with Reduced Toxicity and Metastasis

References

• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–269. doi:10.1007/s00404-015-3859-y
   PubMed Web of Science ®Google Scholar
• Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879–893.e13. doi:10.1016/j.cell.2018.03.041
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–198. doi:10.1158/2159-8290.CD-18-1177
   PubMed Web of Science ®Google Scholar
• Demiroglu-Zergeroglu A, Turhal G, Topal H, et al. Anti-carcinogenic effects of halofuginone on lung-derived cancer cells. Cell Biol Int. 2020;44(9):1934–1944. doi:10.1002/cbin.11399
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P. Pembrolizumab plus chemotherapy in triple-negative breast cancer - authors’ reply. Lancet. 2021;398(10294):24–25. doi:10.1016/S0140-6736(21)00374-3
   PubMed Web of Science ®Google Scholar
• Pines M, Spector I. Halofuginone - the multifaceted molecule. Molecules. 2015;20(1):573–594. doi:10.3390/molecules20010573
   PubMed Web of Science ®Google Scholar
• Elahi-Gedwillo KY, Carlson M, Zettervall J, et al. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79(2):372–386. doi:10.1158/0008-5472.CAN-18-1334
   PubMed Web of Science ®Google Scholar
• Kim Y, Sundrud MS, Zhou C, et al. Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells. Proc Natl Acad Sci USA. 2020;117(16):8900–8911. doi:10.1073/pnas.1913788117
   PubMed Web of Science ®Google Scholar
• Yee KO, Connolly CM, Pines M, et al. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther. 2006;5(2):218–224. doi:10.4161/cbt.5.2.2419
   PubMed Web of Science ®Google Scholar
• Xia X, Wang X, Zhang S, et al. miR-31 shuttled by halofuginone-induced exosomes suppresses MFC-7 cell proliferation by modulating the HDAC2/cell cycle signaling axis. J Cell Physiol. 2019;234(10):18970–18984. doi:10.1002/jcp.28537
   PubMed Web of Science ®Google Scholar
• de Jonge MJ, Dumez H, Verweij J, et al. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer. 2006;42(12):1768–1774. doi:10.1016/j.ejca.2005.12.027
   PubMed Web of Science ®Google Scholar
• Khalid S, Ahmad N, Khizar S, et al. Magnetic polymer colloids for ultrasensitive molecular imaging. In: Magnetic Polymer Colloids for Ultrasensitive Molecular Imaging. Magnetic Nanoparticles in Human Health and Medicine: Current Medical Applications and Alternative Therapy of Cancer. Wiley; 2021:978–1119754671.
   Google Scholar
• Alomari M, Almahasheer A, Jermy BR, et al. Impact of poly (styrene-acrylic acid) latex nanoparticles on colorectal and cervical cancer cells. Polymers. 2021;13(13):2025. doi:10.3390/polym13132025
   PubMed Web of Science ®Google Scholar
• Li W, Xue J, Xu H. Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy. Int J Nanomedicine. 2019;14:1011–1026. doi:10.2147/IJN.S189864
   PubMed Web of Science ®Google Scholar
• Lammari N, Tarhini M, Miladi K, et al. Encapsulation methods of active molecules for drug delivery. In: Chappel E, editor. Drug Delivery Devices and Therapeutic Systems. Academic Press; 2021:289–306.
   Google Scholar
• Zuo R, Zhang J, Song X, et al. Encapsulating halofuginone hydrobromide in TPGS polymeric micelles enhances efficacy against triple-negative breast cancer cells. Int J Nanomedicine. 2021;16:1587–1600. doi:10.2147/IJN.S289096
   PubMed Web of Science ®Google Scholar
• Fedi A, Vitale C, Ponschin G, et al. In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: a systematic review. J Control Release. 2021;335:247–268. doi:10.1016/j.jconrel.2021.05.028
   PubMed Web of Science ®Google Scholar
• Stecklair KP, Hamburger DR, Egorin MJ, et al. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2001;48(5):375–382. doi:10.1007/s002800100367
   PubMed Web of Science ®Google Scholar
• Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000;14(15):2477–2485. doi:10.1096/fj.00-0292com
   PubMed Web of Science ®Google Scholar
• Guo L, Xie G, Wang R, et al. Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy? BMC Cancer. 2021;21(1):717. doi:10.1186/s12885-021-08429-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SM, Partridge AH. Management of breast cancer in very young women. Breast. 2015;24(Suppl 2):S154–158. doi:10.1016/j.breast.2015.07.036
   PubMed Web of Science ®Google Scholar
• Golshan M, Loibl S, Wong SM, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial. JAMA Surg. 2020;155(3):e195410. doi:10.1001/jamasurg.2019.5410
   PubMed Web of Science ®Google Scholar
• Xia X, Wang L, Zhang X, et al. Halofuginone-induced autophagy suppresses the migration and invasion of MCF-7 cells via regulation of STMN1 and p53. J Cell Biochem. 2018;119(5):4009–4020. doi:10.1002/jcb.26559
   PubMed Web of Science ®Google Scholar
• González-González A, Muñoz-Muela E, Marchal JA, et al. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple-negative breast cancer via Smad 2/3/4 and mTORC2 signaling. Clin Cancer Res. 2018;24(22):5697–5709. doi:10.1158/1078-0432.CCR-17-3125
   PubMed Web of Science ®Google Scholar
• Huang H, Brekken RA. The next wave of stroma-targeting therapy in pancreatic cancer. Cancer Res. 2019;79(2):328–330. doi:10.1158/0008-5472.CAN-18-3751
   PubMed Web of Science ®Google Scholar
• Fan Z, Jiang B, Shi D, et al. Selective antitumor activity of drug-free TPGS nano-micelles with ROS-induced mitochondrial cell death. Int J Pharm. 2021;594:120184. doi:10.1016/j.ijpharm.2020.120184
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, et al. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2):174–181. doi:10.1016/j.jconrel.2009.08.010
   PubMed Web of Science ®Google Scholar
• Chai GH, Xu Y, Chen SQ, et al. Transport mechanisms of solid lipid nanoparticles across Caco-2 cell monolayers and their related cytotoxicology. ACS Appl Mater Interfaces. 2016;8(9):5929–5940. doi:10.1021/acsami.6b00821
   PubMed Web of Science ®Google Scholar
• Wang Y. Transport Mechanism of Polymannuronic Acid and Polyguronic Acid Across Caco-2 Cell Monolayer [D]. Shandong University; 2020.
   Google Scholar
• Zhang S, Pang G, Chen C, et al. Effective cancer immunotherapy by Ganoderma lucidum polysaccharide-gold nanocomposites through dendritic cell activation and memory T cell response. Carbohydr Polym. 2019;205:192–202. doi:10.1016/j.carbpol.2018.10.028
   PubMed Web of Science ®Google Scholar
• Boix-Montesinos P, Soriano-Teruel PM, Armiñán A, et al. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev. 2021;173:306–330. doi:10.1016/j.addr.2021.03.018
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang C, Zhang X, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019;14(1):89–97. doi:10.1038/s41565-018-0319-4
   PubMed Web of Science ®Google Scholar
• Yang M, Li J, Gu P, et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2020;6(7):1973–1987. doi:10.1016/j.bioactmat.2020.12.010
   PubMed Web of Science ®Google Scholar
• Lu Z, Zou J, Li S, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284–290. doi:10.1038/s41586-020-2054-x
   PubMed Web of Science ®Google Scholar
• Wang H, Shi W, Zeng D, et al. pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nano-micelles to overcome drug resistance and suppress metastasis in lung cancer. J Nanobiotechnology. 2021;19(1):152. doi:10.1186/s12951-021-00895-4
   PubMed Web of Science ®Google Scholar
• Xu Z, Zheng S, Gao X, et al. Mechanochemical preparation of chrysomycin a self-micelle solid dispersion with improved solubility and enhanced oral bioavailability. J Nanobiotechnology. 2021;19(1):164. doi:10.1186/s12951-021-00911-7
   PubMed Web of Science ®Google Scholar
• Fang Z, Pan S, Gao P, et al. Stimuli-responsive charge-reversal nano drug delivery system: the promising targeted carriers for tumor therapy. Int J Pharm. 2020;575:118841. doi:10.1016/j.ijpharm.2019.118841
   PubMed Web of Science ®Google Scholar
• Alomari M, Balasamy RJ, Almohazey D, et al. Nile red-poly (Methyl Methacrylate)/silica nanocomposite particles increase the sensitivity of cervical cancer cells to tamoxifen. Polymers. 2020;12(7):1516. doi:10.3390/polym12071516
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang W, Jiang W, et al. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. J Nanobiotechnology. 2021;19(1):182. doi:10.1186/s12951-021-00919-z
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kutty RV, Luo Z, et al. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra-bright gold nanoclusters. Biomaterials. 2015;39:234–248. doi:10.1016/j.biomaterials.2014.11.008
   PubMed Web of Science ®Google Scholar
• Xiong XY, Pan X, Tao L, et al. Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel. Int J Biol Macromol. 2017;103:1011–1018. doi:10.1016/j.ijbiomac.2017.05.136
   PubMed Web of Science ®Google Scholar
• Panyam J, Zhou WZ, Prabha S, et al. Rapid endo-lysosomal escape of poly(DL-lactide- co glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10):1217–1226. doi:10.1096/fj.02-0088com
   PubMed Web of Science ®Google Scholar
• National archives & records service of office. FDA draft guidance for industry on drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Availability Federal Register. 2012;77(34):9946.
   Google Scholar
• Li XX, Wang Y, Sun NY, et al. Biopharmaceutical classification system research for six commonly used anti-parasitic drugs in chickens. J Nanjing Agric Univ. 2020;43(5):919–926.
   Google Scholar
• Xie Z, Zhang Z, Lv H. Rapamycin loaded TPGS-Lecithins-Zein nanoparticles based on core-shell structure for oral drug administration. Int J Pharm. 2019;568:118529. doi:10.1016/j.ijpharm.2019.118529
   PubMed Web of Science ®Google Scholar
• Du Z, Mao Y, Zhang P, et al. TPGS-galactose-modified polydopamine co-delivery nanoparticles of nitric oxide donor and doxorubicin for targeted chemo-photothermal therapy against drug-resistant hepatocellular carcinoma. ACS Appl Mater Interfaces. 2021;13(30):35518–35532. doi:10.1021/acsami.1c09610
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Costa Lima SA, et al. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci. 2016;463:258–265. doi:10.1016/j.jcis.2015.10.057
   PubMed Web of Science ®Google Scholar
• Bogman K, Zysset Y, Degen L, et al. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin Pharmacol Ther. 2005;77(1):24–32. doi:10.1016/j.clpt.2004.09.001
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166(2):115–123. doi:10.1016/j.jconrel.2012.12.021
   PubMed Web of Science ®Google Scholar
• Sun S, Du X, Fu M, et al. Galactosamine-modified PEG-PLA/TPGS micelles for the oral delivery of curcumin. Int J Pharm. 2021;595:120227. doi:10.1016/j.ijpharm.2021.120227
   PubMed Web of Science ®Google Scholar
• Chen T, Tu L, Wang G, et al. Multi-functional chitosan polymeric micelles as oral paclitaxel delivery systems for enhanced bioavailability and anti-tumor efficacy. Int J Pharm. 2020;578:119105. doi:10.1016/j.ijpharm.2020.119105
   PubMed Web of Science ®Google Scholar
• Zhang E, Chu F, Xu L, et al. Use of fluorescein isothiocyanate isomer I to study the mechanism of intestinal absorption of fucoidan sulfate in vivo and in vitro. Biopharm Drug Dispos. 2018;39(6):298–307. doi:10.1002/bdd.2137
   PubMed Web of Science ®Google Scholar
• Ramani VC, Lemaire CA, Triboulet M, et al. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. Breast Cancer Res. 2019;21(1):98. doi:10.1186/s13058-019-1182-4
   PubMed Web of Science ®Google Scholar
• Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer. 2010;102(3):561–569. doi:10.1038/sj.bjc.6605491
   PubMed Web of Science ®Google Scholar
• Guo B, Wu S, Zhu X, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39(1):e102190. doi:10.15252/embj.2019102190
   PubMed Web of Science ®Google Scholar
• Taras D, Blanc JF, Rullier A, et al. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia. 2006;8(4):312–318. doi:10.1593/neo.05796
   PubMed Web of Science ®Google Scholar
• Spector I, Zilberstein Y, Lavy A, et al. Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. PLoS One. 2012;7(7):e41833. doi:10.1371/journal.pone.0041833
   PubMed Web of Science ®Google Scholar
• Zcharia E, Atzmon R, Nagler A, et al. Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs. 2012;23(10):1022–1031. doi:10.1097/CAD.0b013e328357d186
   PubMed Web of Science ®Google Scholar